Biomarin Pharmaceutical Stock News

NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the Class Period), of the important December 22, 2021 lead plaintiff deadline .

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 6,000 shares of the businesss stock in a transaction that occurred on Wednesday, December 15th. The stock was sold at an average price of $82.71, for a total transaction of $496,260.00. The sale was disclosed in a legal filing with the SEC, which is accessible through []

(PR-inside.com) LOS ANGELES, CA / ACCESSWIRE / December 17, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit againstBioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ:BMRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company''s securities between January 13, 2020, and September 3, 2021, inclusive (the ''''Class Period''''), are encouraged to contact the firm before December 21, 2021. If you are a shareholder who suffered a loss, click here to participate. We also ..

SAN RAFAEL, Calif., Dec. 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former CEO of Celgene Corporation,

Brokerages predict that BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will post sales of $442.50 million for the current quarter, Zacks reports. Nine analysts have provided estimates for BioMarin Pharmaceutical’s earnings, with the highest sales estimate coming in at $469.10 million and the lowest estimate coming in at $424.00 million. BioMarin Pharmaceutical posted sales of $452.12 million during […]

(PR-inside.com) LOS ANGELES, CA / ACCESSWIRE / December 15, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit againstBioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ:BMRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company''s securities between January 13, 2020, and September 3, 2021, inclusive (the ''''Class Period''''), are encouraged to contact the firm before December 21, 2021. If you are a shareholder who suffered a loss, click here to participate. We also ..

NEW YORK, Dec. 14, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the "Class Period"), of the important December 22,

SAN DIEGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) securities between January 13, 2020 and September 3, 2021, both dates inclusive (the Class Period) have until next Wednesday, December 22, 2021 to seek appointment as lead plaintiff in Berlinger v. BioMarin Pharmaceutical Inc. , No. 21-cv-08254 (N.D. Cal.). Commenced on October 22, 2021, the BioMarin class action lawsuit charges BioMarin as well as certain of its top executives with violations of the Securities Exchange Act of 1934.

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / December 14, 2021 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) alleging that the Company violated federal securities laws. Class Period: January 13, 2020 to September 3, 2021Lead Plaintiff Deadline: December 22, 2021No obligation or cost to you. Learn more about your recoverable losses in BMRN:https://www.kleinstocklaw.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?wire=1 BioMarin Pharmaceutical Inc. NEWS - BMRN NEWS CLASS ACTION CASE DETAILS: The filed complaint alleges that BioMarin Pharmaceutical Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) BMN 307, an Adeno-Associated Virus Vector-Mediated ..

(PR-inside.com) LOS ANGELES, CA / ACCESSWIRE / December 14, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit againstBioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ:BMRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company''s securities between January 13, 2020, and September 3, 2021, inclusive (the ''''Class Period''''), are encouraged to contact the firm before December 21, 2021. If you are a shareholder who suffered a loss, click here to participate. We also ..

Private Advisor Group LLC acquired a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the third quarter, Holdings Channel.com reports. The firm acquired 4,185 shares of the biotechnology companys stock, valued at approximately $323,000. Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Lake []

Related Stocks: PG , BMRN , UNH , EOG , CME , MMC , LSI , SYK , EFX , RE , BKNG , SHW , HSY , SCHW , QCOM , ACN , EQIX , XYL ,

The Cell and Gene Therapy Market covers the present scenario (with the base year being 2021) and the growth prospects of global Cell and Gene Therapy market for 20212028. The report discusses the key drivers influencing market growth, opportunities, the

Los Angeles, USA, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Phenylketonuria Pipeline Shows Rapid Progress in Clinical Trials | DelveInsight There are approximately 15+ key companies developing the Phenylketonuria therapies. In the upcoming years, many new products such as CNSA-001/PTC923 (PTC Therapeutics), HMI-102 (Homology Medicines), and SYNB1618 (Synlogic) are also expected to enter the Phenylketonuria market. PTC-923 is expected to be the most promising drug among all the upcoming therapies. DelveInsight''s " Phenylketonuria Pipeline Insight " report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Phenylketonuria pipeline landscapes. It comprises Phenylketonuria pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Phenylketonuria therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Phenylketonuria pipeline products. Some of the key takeaways from the Phenylketonuria Pipeline Report Major companies such as Synlogic, Homology Medicines, PTC therapeutics, Rubius Therapeutics, NestlÃ, BioMarin, SOM Biotech, Evox Therapeutics, Moderna Therapeutics, Orpharma, Generation Bio, Erydel, Janana therapeutics, American gene technologies, Applied Pharma Research and others are developing potential drug candidates to improve the Phenylketonuria treatment scenario.

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / December 7, 2021 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of BioMarin Pharmaceutical Inc. ("BioMarin") (NASDAQ:BMRN) between January 13, 2020 and September 3, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Northern District of California. To get more information go to: https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?prid=21437&wire=5 or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500. There is no cost or obligation to you. BioMarin ..